Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of SKLB1028 with Itraconazole, Gemfibrozil, or Rifampicin
NCT05069870Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ruserontinib in acute myeloid leukemia (AML) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Maximum concentration up to 22 days, Area under the concentration-time curve from 0 to last measurable concentration up to 22 days and 1 more. Status: unknown.
02
Drugs
ruserontinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05069870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05069870.